Gastric Cancer, Gastroesophageal Junction Cancer
7
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
IMmune Proteomics to Predict NeoAdjuvant Chemotherapy and ImmunoTherapy Response in Gastric Cancer
MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma